Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Clin Cancer Res. 2016 Jun 29;23(3):677–686. doi: 10.1158/1078-0432.CCR-16-0558

Fig 4. Combination of cetuximab and MM-121 inhibits both PI3K/AKT and ERK signaling pathways.

Fig 4

UMSCC1-P (A) and UMSCC1-C (B) cells were treated with 2µg/mL cetuximab, 125µg/mL MM-121, and the combination, respectively. As shown in (A) and (B), after 48 hours of treatment, AKT and ERK activation was simultaneously ablated by the combination compared to single drugs and the control. The inhibition of pAKT was greater by MM-121 than cetuximab in both cell lines (figure represents 1 of 3 experiments).